Trevena, Inc. is a privately held pharmaceutical company focused on discovering and developing the next generation of G-protein coupled receptor (GPCR) targeted medicines.
The Company's unique linked portfolio combines a powerful, proprietary and efficient drug discovery platform with extensive discovery and development experience to yield a rich pipeline of breakthrough medicines. Trevena's drug discovery technology is based on the groundbreaking research from the laboratories of leading scientists in the field - Robert J. Lefkowitz, M.D. and Howard A. Rockman, M.D. of Duke University Medical Center.
7/14/10Trevena Secures $35 Million in Series B Funding
6/11/10Trevena Data Showcasing GPCR Biased Ligands Featured at Scientific Conferences
5/19/10SCYNEXIS and Trevena Announce Strategic Collaboration to Enhance Discovery of Biased GPCR Ligands
